Ceribell, Inc. (CBLL) — SEC Financial Statements & Analysis

Ceribell, Inc. (CBLL) is a electromedical & electrotherapeutic apparatus company, incorporated in DE. Ceribell, Inc. trades on Nasdaq as: CBLL. Ceribell, Inc. (CBLL)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-10. Based on that filing, Ceribell, Inc. carries a market cap of $739.72M, a P/E ratio of -11.21x, a P/B ratio of 5.76x, a P/S ratio of 7.25x, an enterprise value of $727.04M, and an EV/EBITDA multiple of -10.57x. On profitability, it posts a gross margin of 88.90%, an operating margin of -68.62%, a net margin of -64.73%, a Return on Equity (ROE) of -43.93%, a Return on Assets (ROA) of -35.29%, and a Return on Invested Capital (ROIC) of -51.54%. Per share, it reports EPS of $-1.74, diluted EPS of $-1.74, free cash flow per share of $-1.44, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -4.83% year-over-year, net income growth of -1.31% year-over-year, and EPS growth of -5.82% year-over-year. On the balance sheet, it maintains a current ratio of 9.18x, a quick ratio of 8.57x, working capital of $140.65M, a debt-to-equity ratio of 0.30x, a debt ratio of 0.23, an interest coverage ratio of -38.57x, free cash flow of $-54.72M (TTM), and net debt of $-12.68M. Figures sourced from SEC EDGAR.

Market Cap

$739.72M

P/E TTM

-11.21x

EPS TTM

$-1.74

P/B TTM

5.76x

ROE TTM

-43.93%

ROA TTM

-35.29%

Debt To Equity

0.30x

Free Cash Flow TTM

$-54.72M

Net Revenue TTM Growth 1Y

-4.83%

Data as of 2026-06-30 · Source: SEC EDGAR